Alembic is currently trading at Rs. 138.00, up by 6.05 points or 4.59% from its previous closing of Rs. 131.95 on the BSE.
The scrip opened at Rs. 135.60 and has touched a high and low of Rs. 139.25 and Rs. 135.45 respectively. So far 26955 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 169.00 on 23-Aug-2024 and a 52 week low of Rs. 78.00 on 10-Nov-2023.
Last one week high and low of the scrip stood at Rs. 139.25 and Rs. 129.25 respectively. The current market cap of the company is Rs. 3388.24 crore.
The promoters holding in the company stood at 70.88%, while Institutions and Non-Institutions held 2.05% and 27.08% respectively.
Alembic has reported 48.94% rise in its net profit at Rs 76.60 crore for the quarter ended September 30, 2024 as compared to Rs 51.43 crore for the same quarter in the previous year. Total income of the company increased by 47.69% at Rs 116.69 crore for Q2FY25 as compared to Rs 79.01 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported rise of 49.51% in net profit at Rs 77.31 crore for Q2FY25 as compared to Rs 51.71 crore for the same quarter in the previous year. Total income of the company increased by 47.87% at Rs 118.52 crore for Q2FY25 as compared to Rs 80.15 crore for the corresponding quarter previous year.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1777.65 |
Dr. Reddys Lab | 1194.55 |
Cipla | 1465.65 |
Lupin | 2043.30 |
Zydus Lifesciences | 944.25 |
View more.. |